P-glycoprotein and membrane roles in multidrug resistance

Future Medicinal Chemistry

Volumn 7, Issue 7, 2015, Pages 929-946

  Ferreira, Ricardo J ^a   Dos Santos, Daniel Jva ^b   Ferreira, Maria Jose U ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANESTHETIC AGENT; CHOLESTEROL; DETERGENT; MULTIDRUG RESISTANCE PROTEIN;

CELL FUNCTION; CELL MEMBRANE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; FLUIDIZATION; GENE ACTIVITY; HUMAN; HYDROPHOBICITY; LIPID BILAYER; LIPID COMPOSITION; LIPID RAFT; LIPID SOLUBILITY; MATHEMATICAL MODEL; MEMBRANE FLUIDITY; MEMBRANE STRUCTURE; MULTIDRUG RESISTANCE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; CELL MEMBRANE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 84931097415     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.36     Document Type: Review

References (118)

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 136(5), e359-e386 (2015).
2. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrugresistant cells. Proc. Natl Acad. Sci. USA 85(10), 3580-3584 (1988).
3. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim. Biophys. Acta 948(1), 87-128 (1988).
4. Gottesman MM. Mechanisms of cancer drug resistance. Ann. Rev. Med. 53, 615-627 (2002).
5. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. In: Multi-drug Resistance in Cancer (Volume 596). Zhou J (Ed.). Humana Press, New York, USA, 47-76 (2010).
6. Jardetzky O. Simple allosteric model for membrane pumps. Nature 211(5052), 969-970 (1966).
7. Callaghan R, George AM, Kerr ID. 8.8 Molecular Aspects of the Translocation Process by ABC Proteins. In: Comprehensive Biophysics (Volume 8). Egelman EH (Ed.). Elsevier, Amsterdam, Netherlands, 145-173 (2012).
8. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455(1), 152-162 (1976).
9. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41(5), 1967-1972 (1981).
10. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 44(10), 4303-4307 (1984).
11. Twentyman PR, Fox NE, White DJ. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br. J. Cancer 56(1), 55-57 (1987).
12. Hlt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol. 43(12), 2601-2608 (1992).
13. Hofmann J, Gekeler V, Ise W et al. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem. Pharmacol. 49(5), 603-609 (1995).
14. Nsler V, Pelka-Fleisc R, Gieseler F et al. In vitro efficacy of known P-glycoprotein modulators compared with droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants. Leuk. Lymphoma. 31(5-6), 589-597 (1998).
15. Palmeira A, Sousa E, Vasconcelos MH, Pinto M. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr. Med. Chem. 19(13), 1946-2025 (2012).
16. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53(19), 4595-4602 (1993).
17. Martin C, Berridge G, Mistry P, Higgins CF, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 128(2), 403-411 (1999).
18. Ferreira M-JU, Duarte N, Reis M, Madureira AM, Moln J. Euphorbia and momordica metabolites for overcoming multidrug resistance. Phytochem. Rev. 13(4), 915-935 (2014).
19. Altenberg GA, Vanoye CG, Horton JK, Reuss L, Julie K. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc. Natl Acad. Sci. USA 91(11), 4654-4657 (1994).
20. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase Trends Biochem. Sci. 17(1), 18-21 (1992).
21. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 265(7), 3975-3980 (1990).
22. Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated hoechst 33342 transport out of the lipid bilayer. Eur. J. Biochem. 250(1), 115-121 (1997).
23. Aller SG, Yu J, Ward A et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323(5922), 1718-1722 (2009).
24. Sauna ZE, Ambudkar SV. About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol. Cancer Ther. 6(1), 13-23 (2007).
25. Nagle JF, Tristram-Nagle S. Structure of lipid bilayers. Biochim. Biophys. Acta 1469(3), 159-195 (2000).
26. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 175(4023), 720-731 (1972).
27. Engelman DM. Membranes are more mosaic than fluid. Nature 438(7068), 578-580 (2005).
28. Eytan GD, Regev R, Assaraf YG. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. 271(22), 12897-12902 (1996).
29. Regev R, Eytan GD. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem. Pharmacol. 54(10), 1151-1158 (1997).
30. Fyfe PK, McAuley KE, Roszak AW, Isaacs NW, Cogdell RJ, Jones MR. Probing the interface between membrane proteins and membrane lipids by X-ray crystallography. Trends Biochem. Sci. 26(2), 106-112 (2001).
31. Urbatsch IL, Senior AE. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch. Biochem. Biophys. 316(1), 135-140 (1995).
32. Romsicki Y, Sharom FJ. Interaction of P-glycoprotein with defined phospholipid bilayers: a differential scanning calorimetric study. Biochemistry 36(32), 9807-9815 (1997).
33. Romsicki Y, Sharom FJ. The ATPase and ATP-binding functions of P-glycoprotein. Modulation by interaction with defined phospholipids. Eur. J. Biochem. 256(1), 170-178 (1998).
34. Romsicki Y, Sharom FJ. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38(21), 6887-6896 (1999).
35. Oleinikov VA, Fleury F, Ianoul A, Zaitsev S, Nabiev I. P-glycoprotein effect on the properties of its natural lipid environment probed by Raman spectroscopy and Langmuir-Blodgett technique. FEBS Lett. 580(20), 4953-4958 (2006).
36. Lu P, Liu R, Sharom FJ. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur. J. Biochem. 268(6), 1687-1697 (2001).
37. Clay AT, Sharom FJ. Lipid bilayer properties control membrane partitioning, binding and transport of P-glycoprotein substrates. Biochemistry 52(2), 343-354 (2013).
38. Raggers RJ, Pomorski T, Holthuis JCM, Kin N, van Meer G. Lipid traffic: the ABC of transbilayer movement. Traffic 1(3), 226-234 (2000).
39. Eckford PDW, Sharom FJ. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 389(Pt 2), 517-526 (2005).
40. Marcoux J, Wang SC, Politis A et al. Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. Proc. Natl Acad. Sci. USA 110(24), 9704-9709 (2013).
41. Lucas X, Simon S, Schubert R, Gther S. Discovery of the inhibitory effect of a phosphatidylinositol derivative on P-glycoprotein by virtual screening followed by in vitro cellular studies. PLoS ONE 8(4), e60679 (2013).
42. Smit JJM, Schinkel AH, Elferink RPJO et al. Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75(3), 451-462 (1993).
43. Mauad TH, van Nieuwkerk CM, Dingemans KP et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145(5), 1237-1245 (1994).
44. Yeagle PL. Cholesterol and the cell membrane. Biochim. Biophys. Acta 822(3-4), 267-287 (1985).
45. Yeagle PL. Modulation of membrane function by cholesterol. Biochimie 73(10), 1303-1310 (1991).
46. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs J. Membr. Biol. 160(3), 161-175 (1997).
47. Batetta B, Pani A, Putzolu M et al. Correlation between cholesterol esterification, MDR1 gene expression and rate of cell proliferation in CEM and MOLT4 cell lines. Cell Prolif. 32(1), 49-61 (1999).
48. Orlowski S, Martin S, Escargueil A. P-glycoprotein and "lipid rafts": some ambiguous mutual relationships (floating on them, building them or meeting them by chance). Cell Mol. Life Sci. 63(9), 1038-1059 (2006).
49. Saeki T, Shimabuku AM, Ueda K, Komano T. Specific drug binding by purified lipid-reconstituted P-glycoprotein: Dependence on the lipid composition. Biochim. Biophys. Acta 1107(1), 105-110 (1992).
50. Frard F, Garnier-Suillerot A. Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature. Biochim. Biophys. Acta 1389(1), 13-22 (1998).
51. Rothnie A, Theron D, Soceneantu L et al. The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Eur. Biophys. J. 30(6), 430-442 (2001).
52. Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc. Natl Acad. Sci. USA 99(16), 10347-10352 (2002).
53. Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol. Pharmacol. 66(5), 1332-1339 (2004).
54. Gayet L, Dayan G, Barakat S et al. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry 44(11), 4499-4509 (2005).
55. Meyer dos Santos S, Weber C-C, Franke C, Mler WE, Eckert GP. Cholesterol: coupling between membrane microenvironment and ABC transporter activity. Biochem. Biophys. Res. Commun. 354(1), 216-221 (2007).
56. Barakat S, Gayet L, Dayan G et al. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis. Biochem. J. 388(Pt 2), 563-571 (2005).
57. Bucher K, Belli S, Wunderli-Allenspach H, Krer SD. P-glycoprotein in proteoliposomes with low residual detergent: the effects of cholesterol. Pharm. Res. 24(11), 1993-2004 (2007).
58. Eckford PDW, Sharom FJ. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47(51), 13686-13698 (2008).
59. Fenyvesi F, Fenyvesi E, Szente L et al. P-glycoprotein inhibition by membrane cholesterol modulation. Eur. J. Pharm. Sci. 34(4-5), 236-242 (2008).
60. Tamashevski AV, Kozlova NM, Goncharova NV, Zubritskaya GP, Slobozhanina EI. Effect of cholesterol on the functional activity of proteins responsible for the resistance of human lymphocytes to xenobiotics. Biofizika 56(3), 436-443 (2011).
61. Belli S, Elsener PM, Wunderli-Allenspach H, Krer SD. Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities. J. Pharm. Sci. 98(5), 1905-1918 (2009).
62. Pike LJ. Rafts defined: a report on the keystone symposium on lipid rafts and cell function. J. Lipid Res. 47(7), 1597-1598 (2006).
63. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 387(6633), 569-572 (1997).
64. Pike LJ. Lipid rafts: bringing order to chaos. J. Lipid Res. 44(4), 655-667 (2003).
65. Pike LJ. The challenge of lipid rafts. J. Lipid Res. 50(Suppl.), s323-s328 (2009).
66. Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj. J. 17(3-4), 253-259 (2000).
67. Scheiffele P, Roth MG, Simons K. Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J. 16(18), 5501-5508 (1997).
68. Bretscher MS, Munro S. Cholesterol and the Golgi apparatus. Science 261(5126), 1280-1281 (1993).
69. Barman S, Nayak DP. Analysis of the transmembrane domain of influenza virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and raft association. J. Virol. 74(14), 6538-6545 (2000).
70. Scheiffele P, Peren J, Simons K. N-glycans as apical sorting signals in epithelial cells. Nature 378(6552), 96-98 (1995).
71. Modok S, Heyward C, Callaghan R. P-glycoprotein retains function when reconstituted into a sphingolipid-and cholesterol-rich environment. J. Lipid Res. 45(10), 1910-1918 (2004).
72. Garc-Sz AJ, Chiantia S, Salgado J, Schwille P. Pore formation by a Bax-derived peptide: effect on the line tension of the membrane probed by AFM. Biophys. J. 93(1), 103-112 (2007).
73. Ghetie M-A, Crank M, Kufert S, Pop I, Vitetta E. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J. Immunother. 29(5), 536-544 (2006).
74. Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin. Cancer Res. 5(12), 3920-3927 (1999).
75. Ward AB, Szewczyk P, Grimard V et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc. Natl Acad. Sci. USA. 110(33), 13386-13391 (2013).
76. Ferreira RJ, Ferreira MJU, dos Santos DJVA. Insights on P-Glycoprotein's efflux mechanism obtained by molecular dynamics simulations. J. Chem. Theory Comput. 8(6), 1853-1864 (2012).
77. Ferreira RJ, Ferreira M-JU, dos Santos DJVA. Reversing cancer multidrug resistance: insights into the efflux by ABC transports from in silico studies. WIREs Comput. Mol. Sci. 5(1), 27-55 (2015).
78. Woodcock DM, Jefferson S, Linsenmeyer ME et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50(14), 4199-4203 (1990).
79. Woodcock DM, Linsenmeyer ME, Chojnowski G et al. Reversal of multidrug resistance by surfactants. Br. J. Cancer 66(1), 62-68 (1992).
80. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J. Biol. Chem. 267(35), 24995-25002 (1992).
81. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur. J. Biochem. 259(1-2), 18-24 (1999).
82. Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16(4-5), 237-246 (2002).
83. Kiss L, Hellinger E, Pilbat A-M et al. Sucrose Esters Increase Drug Penetration, But Do Not Inhibit P-Glycoprotein in Caco-2 Intestinal Epithelial Cells. J. Pharm. Sci. 103(10), 3107-3119 (2014).
84. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys. 319(1), 309-315 (1995).
85. Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS Lett. 274(23), 6204-6214 (2007).
86. Li-Blatter X, Nervi P, Seelig A. Detergents as intrinsic P-glycoprotein substrates and inhibitors. Biochim. Biophys. Acta 1788(10), 2335-2344 (2009).
87. Nervi P, Li-Blatter X, Aismaa P, Seelig A. P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity. Biochim. Biophys. Acta 1798(3), 515-525 (2010).
88. Shapiro AB, Ling V. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. Eur. J. Biochem. 254(1), 181-188 (1998).
89. Chen Y, Pant AC, Simon SM. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res. 61(21), 7763-7769 (2001).
90. Siarheyeva A, Lopez JJ, Glaubitz C. Localization of multidrug transporter substrates within model membranes. Biochemistry 45(19), 6203-6211 (2006).
91. Mankhetkorn S, Garnier-Suillerot A. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur. J. Pharmacol. 343(2-3), 313-321 (1998).
92. Omote H, Al-Shawi MK. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys. J. 90(11), 4046-4059 (2006).
93. Al-Shawi MK, Omote H. The remarkable transport mechanism of P-glycoprotein: a multidrug transporter. J. Bioenerg. Biomembr. 37(6), 489-496 (2005).
94. Desai PV, Raub TJ, Blanco M-J. How hydrogen bonds impact P-glycoprotein transport and permeability. Bioorgan. Med. Chem. Lett. 22(21), 6540-6548 (2012).
95. Ferreira RJ, Ferreira MJU, dos Santos DJVA. Drug adsorption to P-glycoprotein and lipid bilayer induces an asymmetrical NBD contact and different internal cavity volumes according to its efflux propensity (submitted).
96. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem. Pharmacol. 53(4), 587-596 (1997).
97. Van Hell AJ, Melo MN, van Blitterswijk WJ et al. Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. Sci. Rep. 3, 1949 (2013).
98. Michalak K, Hendrich A, Wesoowska O, Poa A. Compounds that modulate multidrug resistance in cancer cells. Cell Mol. Biol. Lett. 6(2), 362-368 (2001).
99. Wesoowska O, Hendrich AB, Motohashi N et al. Presence of anionic phospholipids rules the membrane localization of phenothiazine type multidrug resistance modulator. Biophys. Chem. 109(3), 399-412 (2004).
100. Cielik-Boczula K, Switek P, Jaszczyszyn A et al. Phase separation in phosphatidylcholine membrane caused by the presence of a pyrimidine analogue of fluphenazine with high anti-multidrug-resistance activity. J. Phys. Chem. B. 118(13), 3605-3615 (2014).
101. Pajeva IK, Todorov DK, Seydel J. Membrane effects of the antitumor drugs doxorubicin and thaliblastine: comparison to multidrug resistance modulators verapamil and transflupentixol. Eur. J. Pharm. Sci. 21(2-3), 243-250 (2004).
102. Vijayaraghavalu S, Peetla C, Lu S, Labhasetwar V. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol. Pharm. 9(9), 2730-2742 (2012).
103. Yun U-J, Lee J-H, Koo KH et al. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochem. Pharmacol. 85(10), 1441-1453 (2013).
104. Zhao R, Liu L, Wang Y, Xiao Z. Vinegar-baked Radix bupleuri modulates the cell membrane constituents and inhibits the P-gp activity in rat hepatocytes. BMC Complement. Altern. Med. 14, 357 (2014).
105. Meier M, Li-Blatter X, Seelig A, Seelig J. Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity. Biophys. J. 91, 2943-2955 (2006).
106. Aismaa P, Gatlik-Landwojtowicz E, Seelig A. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle. Biochemistry 47(38), 10197-10207 (2008).
107. Wielinga PR, Westerhoff HV, Lankelma J. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Eur. J. Biochem. 267(3), 649-657 (2000).
108. Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ, Korzekwa K. Compartmental models for apical efflux by P-glycoprotein-part 1: evaluation of model complexity. Pharm. Res. 31(2), 347-359 (2014).
109. Korzekwa K, Nagar S. Compartmental models for apical efflux by P-glycoprotein: part 2-a theoretical study on transporter kinetic parameters. Pharm. Res. 31(2), 335-346 (2014).
110. Rauch C, Paine SW, Littlewood P. Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity Application to P-glycoprotein-mediated multidrug resistance (MDR). Biochim. Biophys. Acta 1830(11), 5112-5118 (2013).
111. Hartz AMS, Bauer B, Fricker G, Miller DS. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol. 69(2), 462-470 (2006).
112. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc. Natl Acad. Sci. USA 109(39), 15930-15935 (2012).
113. Zembruski NCL, Nguyen CDL, Theile D et al. Liposomal sphingomyelin influences the cellular lipid profile of human lymphoblastic leukemia cells without effect on P-glycoprotein activity. Mol. Pharm. 10(3), 1020-1034 (2013).
114. Qiu L, Zheng C, Zhao Q. Mechanisms of drug resistance reversal in Dox-resistant MCF-7 cells by pH-responsive amphiphilic polyphosphazene containing diisopropylamino side groups. Mol. Pharm. 9(5), 1109-1117 (2012).
115. Kobayashi E, Iyer AK, Hornicek FJ, Amiji MM, Duan Z. Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin. Orthop. Relat. Res. 471(3), 915-925 (2013).
116. Chen C-K, Law W-C, Aalinkeel R et al. Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells. Nanoscale 6(3), 1567-1572 (2014).
117. Qiu L, Qiao M, Chen Q et al. Enhanced effect of pHsensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials 35(37), 9877-9887 (2014).
118. Singh MS, Lamprecht A. Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin. Int. J. Pharm. 478(2), 745-752 (2014).